Answers are grounded in this paper and cite their sources.
Gynecologic cancers represent a significant part of the global burden of cancer and healthcare expenditure. This review systematically summarizes and characterizes the cost inputs for grade ≥ 3 adverse events (AEs) used in economic evaluations of immune checkpoint inhibitor (ICI)-based treatment for gynecologic cancers. PubMed, Cochrane Library, and Scopus were comprehensively searched for economic evaluations of ICI-based treatment in endometrial, cervical, or ovarian cancer published between June 12, 2018 and February 28, 2026. Consolidated Health Economic Evaluation Reporting Standards 2022 statement was utilized to evaluate reporting completeness of each study. Cost inputs were extracted as reported, adjusted to 2026 prices using country-specific consumer price indices, and standardized to 2026 international dollars (I$2026) using purchasing power parity conversion rates reported by the International Monetary Fund. Cost inputs were described by study, cancer type, and AE without pooling. Forty-two economic evaluations were included (cervical 15, endometrial 25, and ovarian 2). Twenty-eight (67%) were conducted in the United States (US) and seven (17%) in China. ICI- based treatment was the intervention in all studies. Grade ≥ 3 hematologic AEs, involving neutropenia, anemia, leukopenia, and thrombocytopenia, were the most frequently modelled grade ≥ 3 AEs and were assigned the highest cost inputs. Cost inputs varied markedly by cancer type, treatment regimen, AE type, and healthcare system context. Cost inputs used in the few Chinese economic evaluations were numerically lower than those in the US and other high-income countries. Ovarian cancer was only two studies and reported only unspecified AE costs. Pembrolizumab was the most frequently analyzed ICI ( n = 28; 66.7%), followed by dostarlimab ( n = 8; 19%) and atezolizumab ( n = 6; 14%) of the total studies. The cost inputs derive from differing costing methods, data sources, and healthcare systems and are not directly comparable. The evidence remains limited particularly for ovarian cancer and countries other than the US and China. Generating localized real-world data is essential to improve economic evaluations, inform value-based policy and clinical decisions, and optimize sustainable healthcare resource allocation.
No takes yet. Share an insight, caveat, or question.
Almalki et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: